Product
Decitabine + Cedazuridine
Aliases
ASTX727, Decitabine and cedazuridine
5 clinical trials
6 indications
Indication
Acute Myeloid LeukemiaIndication
Recurrent Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromeIndication
Chronic Myelomonocytic LeukemiaIndication
Myelodysplastic SyndromesClinical trial
An Open-label Two Strata Study of Bisantrene in Combination With Cytarabine Arabinoside or Bisantrene in Combination With Oral Decitabine/Cedazuridine for the Treatment of Acute Myeloid Leukemia Patients With Extramedullary DiseaseStatus: Withdrawn, Estimated PCD: 2023-08-31
Clinical trial
An Open-label, Crossover, Pharmacokinetic and Efficacy Bridging Study of Oral ASTX727 Versus IV Decitabine in Chinese Subjects With Myelodysplastic SyndromesStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase I Study of Oral Decitabine and Cedazuridine (ASTX727) In Combination With Defactinib (VS-6063) as Therapy of Myelodysplastic Syndromes and Low-blast Acute Myeloid LeukaemiaStatus: Recruiting, Estimated PCD: 2024-12-05
Clinical trial
A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects With Relapsed/Refractory Peripheral T-cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Oral Decitabine-Based Maintenance Therapy in Patients With AML in RemissionStatus: Recruiting, Estimated PCD: 2026-12-31